搜索
 >  其他蛋白>VEGF165 >ActiveMax® Human VEGF165 Protein, Tag Free (HPLC-verified)

ActiveMax® Human VEGF165 Protein, Tag Free (HPLC-verified)

分子别名(Synonym)

RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF

表达区间及表达系统(Source)

ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (VE5-H4210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # NP_001165097).

Predicted N-terminus: Ala 27

蛋白结构(Molecular Characterization)

Online(Ala 27 - Arg 191) NP_001165097

This protein carries no "tag".

The protein has a calculated MW of 19.0 kDa (monomer). As a result of glycosylation, the protein migrates as 24 kDa (monomer) under reducing (R) condition, and 43-50 kDa (homodimer) under non-reducing (NR) condition (SDS-PAGE).

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>98% as determined by SDS-PAGE.

>95% as determined by SEC-HPLC.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

No activity loss was observed after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (Cat. No. VE5-H4210) SDS-PAGE gel

ActiveMax® Human VEGF165, Tag Free (HPLC-verified) on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 98%.

SEC-HPLC

ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (Cat. No. VE5-H4210) HPLC images

A SEC-HPLC analysis showing 95% of ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (VE5-H4210) present as active homodimers.

 

活性(Bioactivity)-ELISA

Biotinylated Human ELISA

Immobilized ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (Cat. No. VE5-H4210) at 0.01 μg/mL (100 μL/well) can bind Human VEGF R1, His Tag (Cat. No. VE1-H5220) with a linear range of 4-31 ng/mL (QC tested).

Protocol

Biotinylated Human SPR

Immobilized ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a linear range of 10-156 ng/mL (Routinely tested).

Protocol

Biotinylated Human ELISA

Immobilized ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Bevacizumab and 0.5 μg/mL (100 μL/well) Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a half maximal inhibitory concentration (IC50) of 0.70 μg/mL (Routinely tested).

Protocol

活性(Bioactivity)-SPR

Biotinylated Human SPR

Avastin (Bevacizumab) captured on CM5 chip via ant-human IgG Fc antibodies surface, can bind ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (Cat. No. VE5-H4210) with an affinity constant of 0.776 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol

 

活性(Bioactivity)-Cell based assay

Biotinylated Human CELL_BASE

ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (Cat. No. VE5-H4210) stimulates proliferation of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is 4.216-9.281 ng/ml (Routinely tested).

Protocol

Biotinylated Human CELL_BASE

Inhibition assay shows that the proliferation effect of ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (Cat. No. VE5-H4210) is inhibited by increasing concentration of anti-VEGF mAb (Avastin). The concentration of VEGF165 used is 20 ng/ml. The ED50 is 0.065-0.229 μg/mL (Routinely tested).

Protocol

 

文献引用(Citations)

Amino Acid Sequence

APMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQENPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR

背景(Background)

VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

 

前沿进展

货号/价格

VE5-H4210-20ug / ¥2200

VE5-H4210-50ug / ¥5800

VE5-H4210-1mg (200ug X 5) / ¥20000

开发建议
文档
联系电话:
400-682-2521(全国)
010-57737274(北京)
021-26136428(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
techsupport@acrobiosystems.com
VEGF165靶点信息
英文全称:Vascular endothelial growth factor A
中文全称:血管内皮生长因子A
种类:Homo sapiens
上市药物数量:14详情
临床药物数量:82详情
最高研发阶段:批准上市
查看更多信息

消息提示

请输入您的联系方式,再点击提交!

确定